Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia

Inclusion Criteria: * Adults with the established, pathologically confirmed diagnosis of relapsed AML * AML that has relapsed at least once or is primary induction failure * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Patients must be able to give informed consent * Female patients of childbearing age must have negative pregnancy test * Serum creatinine =\< 2.0 mg/dl * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 5 x upper limit normal (ULN), unless due to Gilbert's, hemolysis or leukemic infiltration * Alkaline phosphatase =\< 5 x ULN, unless due to Gilbert's, hemolysis or leukemic infiltration * Bilirubin =\< 2.0 mg/dl, unless due to Gilbert's, hemolysis or leukemic infiltration * Left ventricular ejection fraction \>= 45% by multi gated acquisition scan (MUGA) or echocardiogram * Baseline Fridericia corrected QT (QTcF) \< 480 msec * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 30 days after study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic, are eligible provided that they are \>= 4 weeks from stem cell infusion, have no active graft-vs-host disease (GVHD), and meet other eligibility criteria * Patients who fail primary induction therapy or relapse after achieving complete remission (CR) are eligible if they have undergone no more than 2 prior cytotoxic regimens (a regimen is described as a distinctive planned collection of agent\[s\] and/or modalities to be utilized together during a cycle or course of therapy; i.e., induction+consolidation with or without stem cell transplant \[SCT\]), \>= 2 weeks off cytotoxic chemotherapy, and \>= 2 weeks off radiation therapy; patients must be off biologic therapies including hematopoietic growth factors \>= 2 weeks; if using hydroxyurea (HU), steroids, imatinib or other tyrosine kinase inhibitors (TKIs), interferon, or other non-cytotoxics for blast count control, patient must be off for \>= 24 hours (hrs) before starting MK-8776 * Fluvoxamine and ciprofloxacin must be stopped 7 days prior to day 1 of therapy, and be excluded during administration of study therapy; if the subject is using any of the other drugs that are cytochrome P4501A2 (CYP1A2) or P-glycoprotein (PgP) inhibitors, substitution should be considered and administration of these drugs should be avoided on the days of administration of MK-8776; in addition, smoking should be avoided and cytochrome P450 3A4 (CYP3A4) substrates with a narrow therapeutic index should be avoided: alfentanil, astemizole, cisapride, cyclosporine, diergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, terfenadine Exclusion Criteria: * Any previous treatment with MK-8776 * Considered refractory or treatment failure to most recent treatment regimen, unless primary refractory * Concomitant chemotherapy, radiation therapy, or immunotherapy * Hyperleukocytosis with \>= 50,000 blasts/uL (if using HU, steroids, tyrosine kinase/src inhibitors (including fms-related tyrosine kinase 3 \[FLT3\] inhibitors), arsenic, interferon or leukapheresis for blast count control, patient must be off those agents for 24 hours prior to beginning ara-C +/- MK-8776) * Acute progranulocytic leukemia (APL, M3) * Active disseminated intravascular coagulation (DIC) * Active central nervous system (CNS) leukemia * Active, uncontrolled infection; patients with infection under active treatment and controlled with antibiotics are eligible * Presence of other life-threatening illness * Patients with mental deficits and/or psychiatric history that preclude them from giving informed consent or from following protocol * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-8776 * History of Fridericia corrected QT (QTcF) prolongation greater than grade 1 or 480 msec * Subjects with the following cardiac risk factors must be excluded: transmural myocardial infarction (MI) within prior 6 months, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack (TIA) or seizure disorder within 6 months prior to study drug administration * Subjects with history of risk factors for torsades de pointes: clinical history of heart failure (New York Heart Association \[NYHA\] class III or IV), hypo- or hyper-kalemia or hypomagnesemia (supplementation to bring levels within normal limits prior to administration of MK-8776 is acceptable) or family history of Long QT Syndrome * Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy or who have a prior history of acquired immunodeficiency syndrome (AIDS) indicator conditions, other than history of lymphoma more than 3 years remote